Kiniksa Pharmaceuticals International (KNSA) Tax Provisions (2017 - 2026)

Kiniksa Pharmaceuticals International (KNSA) has reported Tax Provisions for 10 consecutive years, with $5.7 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Tax Provisions rose 13.24% year-over-year to $5.7 million; the trailing twelve-month figure through Jun 2026 stood at $33.6 million (up 254.67% YoY), and the FY2025 full-year result was $29.9 million, up 324.13% from the prior year.
• Tax Provisions declined to $5.7 million in Q2 2026 per KNSA's latest filing, from $10.1 million in the prior quarter.
• Across five years, Tax Provisions topped out at $10.1 million in Q1 2026 and bottomed at -$177.4 million in Q3 2022.
• Historically, Tax Provisions has averaged -$8.4 million across 5 years, with a median of $4.2 million in 2024.
• The widest YoY moves for Tax Provisions: up 816.67% in 2022, down 150203.39% in 2022.
• Over 5 years, Tax Provisions stood at $2.4 million in 2022, then slumped by 1057.44% to -$22.8 million in 2023, then soared by 64.49% to -$8.1 million in 2024, then surged by 212.1% to $9.1 million in 2025, then tumbled by 37.01% to $5.7 million in 2026.
• According to Business Quant data, Tax Provisions over the past three periods registered $5.7 million, $10.1 million, and $9.1 million for Q2 2026, Q1 2026, and Q4 2025 respectively.